8-K: Nurix Therapeutics: Bexobrutideg Shows Promise in CLL Trials

Nurix Therapeutics announced updated clinical data for bexobrutideg, a BTK degrader, showing high response rates and durable efficacy in chronic lymphocytic leukemia patients.

Summary

• Nurix Therapeutics presented updated clinical data from its Phase 1a/1b study of bexobrutideg (NX-5948) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
• The data, presented at the European Hematology Association Congress (EHA2026), showed bexobrutideg was well tolerated across patient populations, with no dose-limiting toxicities reported.
• In the Phase 1a study of 48 heavily pretreated patients, the objective response rate (ORR) was 83.0% with a median progression-free survival (PFS) of 22.1 months.
• Phase 1b data from earlier-line cohorts showed a high ORR of 92.9% in BTKi-treated, BCL2i-nave patients (Cohort 5) and 84.2% in BTKi-nave patients (Cohort 15).
• Responses were observed in difficult-to-treat subgroups, including those with BTK inhibitor resistance mutations, high-risk molecular features, and CNS involvement.
• The company plans to advance these programs, including a Phase 3 monotherapy program and combination regimens, supported by a collaboration with Roche.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development due to strong efficacy and safety data in a difficult-to-treat patient population, supporting future development and potential market entry.

Positives

• Bexobrutideg demonstrated a high objective response rate (ORR) of 83.0% in heavily pretreated relapsed/refractory CLL/SLL patients in Phase 1a.
• Median progression-free survival (PFS) was 22.1 months in the Phase 1a population.
• Phase 1b data showed a high ORR of 92.9% in BTKi-treated, BCL2i-nave patients (Cohort 5).
• Phase 1b data also showed a high ORR of 84.2% in BTKi-nave patients (Cohort 15).
• Bexobrutideg was well tolerated across all Phase 1a/1b CLL patients (n=142), with no dose-limiting toxicities.
• Responses were observed in challenging patient subgroups, including those with BTK inhibitor resistance mutations, high-risk molecular features, and CNS involvement.
• Treatment discontinuations due to adverse events occurred in only 5.6% of patients.
• The company is advancing Phase 3 monotherapy programs and exploring combination regimens.

Negatives

• Three Grade 5 adverse events were reported, though deemed not related to treatment.
• The Phase 1a population was heavily pretreated, with a median of four prior lines of therapy.
• Many patients in Phase 1a had mutations associated with BTK inhibitor resistance (38.3% BTK, 14.9% PLCG2) and poor prognostic features (44.7% TP53 mutations).

Risks

• Potential for unexpected emergence of adverse events or undesirable side effects during further development.
• Risks and uncertainties related to regulatory review, including under the Hart-Scott-Rodino Antitrust Improvements Act.
• The company may not have adequate resources to fund its clinical and commercial obligations under the Nurix-Roche collaboration.
• The success of bexobrutideg depends on continued positive results in ongoing and future clinical trials, including Phase 3 studies.
• Competition from other BTK inhibitors and novel therapies in the CLL treatment landscape.

Future Outlook

The company plans to launch a broad Phase 3 monotherapy program for bexobrutideg and strengthen the rationale for exploring combination regimens in first- and second-line patients, supported by the collaboration with Roche.

Management Comments

• "These updated data continue to demonstrate the differentiated profile of bexobrutideg, including durable responses in heavily pretreated patients and encouraging activity in patients earlier in their treatment journey."
• "Importantly, responses were observed across patients with difficult-to-treat disease characteristics, including BTK inhibitor resistance mutations, high-risk molecular features and CNS involvement, while maintaining a favorable tolerability profile."
• "With longer follow-up in relapsed/refractory CLL and expansion into earlier-line treatment settings, we continue to see a consistent efficacy and safety profile for bexobrutideg."
• "The durability of responses observed in heavily pretreated patients together with the promising activity seen in BCL2i-nave and BTKi-nave patients further support the broad potential of BTK degradation across all lines of therapy in CLL."
• "These latest findings continue to reinforce our belief that bexobrutideg has the potential to redefine BTK-directed therapy and emerge as a potentially best-in-class treatment for CLL."
• "We look forward to advancing these programs through our recently announced collaboration with Roche."

Industry Context

StockSavvy.ai notes that the positive clinical data for bexobrutideg, a BTK degrader, aligns with the growing trend in oncology towards targeted protein degradation therapies, which aim to offer more precise and potentially more effective treatments for hematological malignancies like CLL.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical data, potentially increasing the company's valuation and future prospects.
• Patients: Potential for a new, effective treatment option for CLL/SLL, especially for those with relapsed/refractory disease or resistance to existing therapies.
• Healthcare Providers: May consider bexobrutideg as a valuable addition to treatment options for CLL/SLL, particularly given its efficacy in difficult-to-treat subgroups.

Next Steps

• Launch a broad Phase 3 monotherapy program for bexobrutideg.
• Explore the use of combination regimens of bexobrutideg in first- and second-line patients.
• Advance programs through the collaboration with Roche.

Key Dates

Recommendation

The updated clinical data for bexobrutideg demonstrates significant efficacy and a favorable safety profile in relapsed/refractory CLL/SLL, including challenging patient subgroups. The high ORR and durable PFS, coupled with promising results in earlier lines of therapy and a strategic collaboration with Roche, suggest strong potential for bexobrutideg to become a best-in-class treatment, warranting a strong buy recommendation.

Keywords

Bexobrutideg, NX-5948, BTK degrader, CLL, SLL, Nurix Therapeutics, Phase 1a/1b study, EHA2026